Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
JERUSALEM, Oct. 31, 2023 (GLOBE NEWSWIRE) -- via IBN -- *Scinai Immunotherapeutics Ltd* (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, announced the publication today of its financial results for the third quarter ended Sept. 30, 2023 and provided a business update.
*THIRD** QUARTER 2023 FINANCIAL SUMMARY*
· *R&D expenses *for the three months ended Sept. 30, 2023 amounted to $1.13 million compared to $1.19 million for the three months ended Sept. 30, 2022.
· *Marketing, general and administrative expenses *for the three months ended Sept. 30, 2023 amounted to $0.97 million compared to $0.96 million for the three months ended Sept. 30, 2022.
· *Total operating expenses *for the three months ended Sept. 30, 2023 amounted to $2.1 million compared to $2.1 million for the three months ended Sept. 30, 2022.
· *Financial income *for the three months ended Sept. 30, 2023 amounted to $5.2 million compared to $6.9 million income for the three months ended Sept. 30, 2022.
· *Net **Income* *(**loss**)* for the three months ended Sept. 30, 2023 amounted to $3.1 million income compared to $4.7 million loss for the three months ended Sept. 30, 2022.As of Sept. 30, 2023, Scinai had cash and cash equivalents of $6.4 million as compared to $14.2 million as of Dec. 31, 2022.
In the nine months ended Sept. 30, 2023, Scinai had an operating loss of $7.8 million and negative cash flows from operating activities of $8.1 million.
A summary of unaudited financial results is included in the tables below.
*BUSINESS UPDATE*
*Strategic **pivot*
· In support of the Company’s strategic pivot, in Sept. 2023, we raised $1.33 million in gross proceeds ($1.08 million in net proceeds) via a registered direct offering with H.C. Wainwright & Co. acting as placement agent.
· In order to extend our cash runway and address the Nasdaq minimum shareholders’ equity compliance issue, our primary creditor, the European Investment Bank (EIB), is currently considering favorably adjusting the terms of the EIB’s financial facility contract with the Company, in particular by extending the facility’s maturity. There is no guarantee that the EIB will approve the adjustment of the terms of the EIB’s financial facility with the Company. In addition, we are implementing a cost saving plan as mentioned in our Q2’23 financial results press release.
· As part of the strategic pivot, in September 2023 the company rebranded as Scinai Immunotherapeutics.*New **CDMO** Business Unit**’s first client*
· In October 2023, the Company closed its first contract to provide CDMO services. We are in advanced contract discussions with several other potential clients. In addition, we are pursuing extensive targeted marketing activities, including participation at major pharmaceutical conferences such as CPHI in Barcelona (October 2023) and BIO-Europe in Munich (November 2023).*Pipeline Development*
· We are aggressively advancing the NanoAb preclinical development. Meaningful ex vivo results for our IL-17 NanoAb tested in human psoriatic skin specimens are anticipated in Q4 ’23, and we continue to expect to enter clinical testing of the NanoAb as a biobetter psoriasis treatment in 2024.
· NanoAbs for treatment of additional autoimmune diseases, such as asthma and wet AMD have been discovered and characterized at Max Planck and University Medical Center Göttingen as part of their research collaboration agreement with Scinai. Scinai holds exclusive options for exclusive licenses at pre agreed financial terms for each of the resulting NanoAbs.
· We are pursuing a strategic partnership for our COVID-19 self-administered inhaled NanoAb which demonstrated highly promising in vivo results in animals as both a therapeutic and prophylactic treatment.*About Scinai Immunotherapeutics Ltd.*
Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com.
*Company Contact*
Joshua Phillipson | +972 8 930 2529 | joshua.phillipson@scinai.com
*Forward-Looking Statements*
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the Company’s cash runway, adjustments to the terms of the EIB’s loan to the Company and compliance with the Nasdaq Listing Rules. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to, the risk that the EIB will not agree to adjust the terms of its loan to the Company, that the Company’s ADSs will not return to compliance with the Nasdaq Listing Rules, that Scinai may not be able to secure additional capital on attractive terms, if at all, and the risk that the Company’s cash runway will be extended; the risk that the therapeutic and commercial potential of NanoAbs will not be met; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the loans under its finance contract with Scinai; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai’s manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 17, 2023. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.
*CONDENSED **BALANCE SHEETS (**Unaudited**)*
*U.S. dollars in thousands **(except share and per share data)* *
*
*
*
*September 30,*
*December 31,*
*2023*
*2022*
*Unaudited*
*Audited*
*ASSETS*
CURRENT ASSETS:
Cash and cash equivalents
6,362
14,075
Restricted cash
122
140
Prepaid expenses and other receivables
228
155
Total current assets
6,712
14,370
NON-CURRENT ASSETS:
Property, plant and equipment, net
10,660
11,245
Operating lease right-of-use assets
1,210
1,452
Total non-current assets
11,870
12,697
Total assets
18,582
27,067
*LIABILITIES AND SHAREHOLDERS’ EQUITY*
CURRENT LIABILITIES:
Trade payables
546
716
Operating lease liabilities
382
382
Other payables
610
1,240
Total current liabilities
1,538
2,338
NON-CURRENT LIABILITIES:
Warrants liability
311
5,329
Loan from others
18,602
20,082
Non-current operating lease liabilities
823
1,078
Total non-current liabilities
19,736
26,489
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY (DEFICIT):
Ordinary shares of no par value: Authorized: 20,000,000,000 shares at September 30, 2023 and at December 31, 2022; Issued and outstanding 1,740,770,784 shares at September 30, 2023 and 989,290,784 shares at December 31, 2022
-
-
Additional paid-in capital
119,053
116,082
Accumulated deficit
(120005
)
(115835
)
Accumulated other comprehensive loss
(1740
)
(2007
)
Total shareholders’ deficit
(2692
)
(1760
)
Total liabilities and shareholders’ deficit
18,582
27,067
*CONDENSED STATEMENTS OF OPERATIONS (Unaudited)*
*U.S. dollars in thousands (except share and per share data)* *Three months ended September 30,*
*Nine months ended September 30,*
*2023*
*2022*
*2023*
*2022*
*Unaudited*
Research and development expenses, net
1,134
1,194
4,583
4,331
Marketing, general and administrative
968
967
3,300
3,708
Total operating loss
2,102
2,161
7,883
8,039
Financial loss (income), net
(5,209
)
(6,939
)
(3,713
)
(7,359
)
Net loss (income)
(3,107
)
(4,778
)
4,170
680
Net Gain loss (Gain) per share attributable to
basic ordinary shareholders,
(0.002
)
(0.01
)
0.002
0.001
diluted ordinary shareholders
(0.002
)
(0.01
)
0.002
0.001
Weighted average number of shares used for computing basic net loss per share
1,876,885,253
781,436,944
1,682,990,012
746,294,693
*CONDENSED**STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)*
*U.S. dollars in thousands (except share and per share data)* *Three months ended*
*September 30,*
*Nine months ended*
*September 30,*
*2023*
*2022*
*2023*
*2022*
*Unaudited*
Net loss (income)
(3,107
)
$
(4,778
)
4,170
680
Other comprehensive (income) loss:
Foreign currency translation adjustments
-
413
267)
(
460
Total comprehensive loss
(3,107
)
(4,365(
3,903
1,140
*CONDENSED STATEMENTS CHANGES IN SHAREHOLDERS’ EQUITY (Unaudited)*
*U.S. dollars in thousands (except share and per share data)* *Three months ended September 30, 2023*
*Ordinary shares*
*Additional paid-in*
*Accumulated*
*Accumulated*
*Total shareholders’* *Number*
*Amount*
*capital*
*comprehensive loss*
*deficit*
*equity*
Balance as of June 30, 2023
1,453,970,784
-
117,740
(1,740
)
(123,112
)
(7,112
)
Exercise of warrants
120,000,000
-
-
-
-
-
Vested RSU's
6,800,000
-
-
-
-
-
Issuance of shares and warrants, net
160,000,000
1,086
1,086
Share-based compensation
-
-
227
-
-
227
Other comprehensive income
-
-
-
-
-
-
Net Gain
-
-
-
-
3,107
3,107
Balance as of September 30, 2023
1,740,770,784
*-*
119,053
(1,740
)
(120,005
)
(2,692
)
*
*
*Nine months ended**September**30, 2023*
*Ordinary shares*
*Additional paid-in*
*Accumulated*
*Accumulated*
*Total shareholders’*
*Number*
*Amount*
*capital*
*comprehensive loss*
*deficit*
*equity*
Balance as of January 1, 2023
989,290,784
-
116,082
(2,007
)
(115,835
)
(1,760
)
Exercise of warrants
584,015,200
-
801
-
-
801
Vested RSU's
7,464,800
-
-
-
-
-
Issuance of shares and warrants, net
160,000,000
1,484
1,484
Share-based compensation
-
-
686
-
-
686
Other comprehensive income
-
-
-
267
-
267
Net loss
-
-
-
-
(4,170
)
(4,170
)
Balance as of September 30, 2023
1,740,770,784
*-*
119,053
(1,740
)
(120,005
)
(2,692
)
*Three months ended June 30, 202**2*
*Ordinary shares*
*Additional paid-in*
*Accumulated*
*Accumulated*
*Total shareholders’*
*Number*
*Amount*
*capital*
*comprehensive loss*
*deficit*
*equity*
Balance as of June 30, 2022
747,153,064
-
$114,335
(2,102
)
(115,497
)
(3,264
)
Share-based compensation
-
341
-
-
341
Other comprehensive loss
-
-
-
(413
)
-
(413
)
Net loss
-
-
-
-
4,778
4,778
Balance as of September 30, 2022,
747,153,064
*-*
114,676
(2,515
)
(110,719
)
1,442
*Nine months ended September 30, 2022*
*Ordinary shares*
*Additional paid-in*
*Accumulated*
*Accumulated*
*Total shareholders’*
*Number*
*Amount*
*capital*
*comprehensive loss*
*deficit*
*equity*
Balance as of January 1, 2022
739,048,544
-
113,076
)2,055
)
(110,039
)
982
Issuance of shares, net of issuance costs of $6
6,000,000
-
216
-
-
216
Vested RSU's
2,104,520
-
-
-
-
-
Expiration of employees options
-
180
-
-
180
Share-based compensation
-
1,204
-
-
1,204
Other comprehensive loss
-
-
-
(460
)
-
(460
)
Net loss
-
-
-
-
(680
)
(680
)
Balance as of September 30, 2022,
747,153,064
*- *
114,676
(2,515
)
(110,719
)
1,442
Starting July 1, 2023 the company’s functional currency is USD.
*CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)*
*U.S. dollars in thousands (except share and per share data)* *Nine months ended
**September 30,*
*2023*
*2022*
*Unaudited*
*Unaudited*
Cash flows from operating activities:
Net loss
(4,170
)
(680
)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment
430
378
Expense of in-process research and development
-
179
Financial expenses related to loan from others
(369
)
(6,948
)
Share-based compensation
686
1,204
Decrease in other receivables
(82
)
96
Warrants revaluation
(3,924
)
-
Changes in operating lease right-of-use assets
(14
)
(10
)
Increase in trade payables
(135
)
(580
)
Changes in operating lease liabilities
-
10
(Decrease) increase in other payables
(579
)
(321
)
Net cash used in operating activities
(8,157
)
(6,672
)
Cash flows from investing activities:
Purchase of property, plant and equipment
(403
)
(566
)
Net cash used in investing activities
(403
)
(566
)
*CONDENSED STATEMENTS OF CASH FLOWS (Unaudited)*
*U.S. dollars in thousands (except share and per share data)* *Nine months ended
**September 30,*
*2023*
*2022*
*Unaudited*
*Unaudited*
Cash flows from financing activities:
Issuance of shares and warrants
1,086
-
Net cash provided by financing activities
1,086
-
Effect of exchange rate changes on cash, cash equivalents and restricted cash
(258
)
(1,826
)
Decrease in cash, cash equivalents and restricted cash
(7,732
)
(9,064
)
Cash, cash equivalents and restricted cash at the beginning of the period
14,215
17,518
Cash, cash equivalents and restricted cash at the end of the period
6,484
8,447
Supplementary disclosure of cash flows activities:
(1) Cash paid during the year for:
Interest
725
-
(2) Non-cash transactions:
Issuance of warrants
1,345
-
Exercise of warrants liability to equity
801
-
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents
6,362
8,310
Restricted cash
122
137
Cash, cash equivalents and restricted cash
6,484
8,447
Notes in the Company’s audited financial reports are an integral part of the financial statements and are filed with the Securities and Exchange Commission.
Corporate Communications:
InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
Editor@InvestorBrandNetwork.com